- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT05305404
Dexametason mot stress och immunsystemets mekanismer bakom alkoholbegär
Dexametason för att inrikta sig på stress och immunsystemförändringar under tidig avhållsamhet hos individer med alkoholmissbruk (AUD)
This is a double-blind, placebo-controlled, proof of concept laboratory study to recruit N=70 (35 Males / 35 Females) non-treatment seeking, heavy drinkers with alcohol use disorder (AUD). It is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving during stress by decreasing basal cortisol, increasing anti-inflammatory cytokine levels and potentially normalizing the immune response to stress.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Faktisk)
Fas
- Tidig fas 1
Kontakter och platser
Studieorter
-
-
New York
-
Stony Brook, New York, Förenta staterna, 11794
- The Health Sciences Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Non-treatment seeking heavy drinking men and women with AUD
- Age range 18-55,
- Body Mass Index (BMI) of 18-35
- Positive ethylglucuronide (EtG) urine toxicology screen for alcohol
- Able to provide informed written and verbal consent
- Able to read English and complete study evaluations
- Good health as verified by screening examination.
Exclusion Criteria:
- Meet criteria for Substance Use Disorder (SUD) or other psychoactive substances, excluding nicotine
- Unable to remain abstinent for five days
- Need for a medically assisted detoxification
- Regular use of steroids, anticonvulsants, sedatives/hypnotics, prescription analgesics, other anti-hypertensives, anti-arrythmics, antiretroviral medications, tricyclic antidepressants, naltrexone, disulfiram, and any other psychoactive medications with the exception of stabilization on Selective Serotonin Re-uptake Inhibitors (SSRIs)
- Psychotic or severely psychiatrically disabled
- Significant underlying medical conditions which would be of potential harm
- Pregnancy or breast feeding women;
- Women using monophasic contraceptives
- Electrocardiogram (EKG) evidence of clinically significant conduction abnormalities, (Bazlett's corrected QT (QTc) interval of >450 msec for men and QTc>470 msec for women).
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Dubbel
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Guanfacine
single dose of dexamethasone (1.5mg) administered orally |
1.5mg oral dexamethasone to be administered once at 11:00PM
Andra namn:
|
|
Placebo-jämförare: Placebo
single dose of placebo administered orally |
oral placebo to be administered once at 11:00PM |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure
|
The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving |
Change from baseline to +5 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure
|
The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving |
Change from baseline to +15 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure
|
The 8-item Alcohol Urges Questionnaire (AUQ) will be used to measure alcohol craving. There are 8 items, each with a Likert scale response from 1 to 7 (1: Strongly Disagree, 7: Strongly Agree). Total possible score of 56. The higher the score the higher the alcohol craving |
Change from baseline to +30 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure
|
A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +5 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure
|
A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +15 minutes following stress exposure
|
|
Alcohol craving as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure
|
A visual analog scale will be used to measure alcohol craving. Participants will be required to rate "how much they are craving alcohol right at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +30 minutes following stress exposure
|
|
Hypothalamic-Pituitary-Adrenal (HPA)-axis response to stress exposure as assessed by cortisol
Tidsram: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma cortisol will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by cortisol
Tidsram: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma cortisol will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by cortisol
Tidsram: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma cortisol will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by Adrenocorticotropic Hormone (ACTH)
Tidsram: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma ACTH will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by ACTH
Tidsram: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma ACTH will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
HPA axis response to stress exposure as assessed by ACTH
Tidsram: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma ACTH will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Interleukin (IL)-10 will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma IL-10 will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma IL-10 will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Interleukin 1 receptor antagonist (IL1-ra) will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma IL1-ra will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma IL1-ra will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma IL-6 will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma IL-6 will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma IL-6 will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Tumor Necrosis Factor alpha (TNFa) will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma TNFa will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma TNFa will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +5 minutes following stress exposure
|
4mls of plasma Tumor Necrosis Factor Receptor 1 (TNFR1) will be collected following exposure to stress |
Change from baseline to +5 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +15 minutes following stress exposure
|
4mls of plasma TNFR1 will be collected following exposure to stress |
Change from baseline to +15 minutes following stress exposure
|
|
Immune system response to stress exposure as assessed by peripheral cytokines
Tidsram: Change from baseline to +30 minutes following stress exposure
|
4mls of plasma TNFR1 will be collected following exposure to stress |
Change from baseline to +30 minutes following stress exposure
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Anxiety as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure
|
A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +5 minutes following stress exposure
|
|
Anxiety as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure
|
A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +15 minutes following stress exposure
|
|
Anxiety as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure
|
A visual analog scale will be used to measure anxiety. Participants will be required to rate "how nervous, anxious or jittery they are feeling at this moment". The scale will be anchored from 1 to 10 (1: Not at all, 10: Extremely) |
Change from baseline to +30 minutes following stress exposure
|
|
Negative Mood as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +5 minutes following stress exposure
|
The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely |
Change from baseline to +5 minutes following stress exposure
|
|
Negative Mood as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +15 minutes following stress exposure
|
The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely |
Change from baseline to +15 minutes following stress exposure
|
|
Negative Mood as assessed using subjective report following stress exposure
Tidsram: Change from baseline to +30 minutes following stress exposure
|
The Differential Emotion Scale will be used to measure negative mood. Participants will be required to rate on a 5-point scale the extent to which an emotional word describes the way they feel at the current time. 1: not at all, 5: Extremely |
Change from baseline to +30 minutes following stress exposure
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Helen C Fox, PhD, Indiana University School of Medicine, Dept. of Psychiatry
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
- Mentala störningar
- Substansrelaterade störningar
- Kemiskt inducerade störningar
- Alkoholrelaterade störningar
- Alkoholism
- Svavelföreningar
- Organiska kemikalier
- Kolväten
- Kolväten, cykliska
- Kolväten, aromatisk
- Polycykliska föreningar
- Graviditet
- Graviditet
- Steroider
- Fusion-ringföreningar
- Steroider, fluorerade
- Bensiverivat
- Sulfonsyror
- Svavelsyror
- Graviditet
- Bensensulfonater
- Arylsulfonater
- Arylsulfonsyror
- Dexametason
- Kalciumdobesilat
Andra studie-ID-nummer
- R21AA029735 (U.S.S. NIH-anslag/kontrakt)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .